Markers of endothelial activation and damage in haematological patients in relation to efficacy of transfusion support: a pilot study.

Markers of endothelial activation and damage in haematological patients in relation to efficacy of transfusion support: a pilot study. - The marker study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31260

Enrollment

Registered

2007-06-01

Start date

2008-01-15

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood diseases Haematological diseases

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age > or 2 platelet transfusions 3. patients with sickle cell disease 4. informed consent

Exclusion criteria

Exclusion criteria: 1. Active cardiovascular disease 2. Recent thrombotic event 3. The usage of Ascal

Design outcomes

Primary

Measure	Time frame
Clinical endpoints: For the hemato-oncological patients: - bleeding complications - transfusion efficacy For the SCD patients - occurence/existence of organ damage Laboratory determination of: P-selectin, activated leukocytes, micro-particles, integrines and cytokines by flowcytometry; Hyaluronic acid, vWF and its propeptide with ELISA technique; and platelet aggregation assays. Gene expression.	—

Countries

Netherlands

Outcome results